SG/PUT/GILEAD SCIENCES/90/0.1/21.06.24 | Delayed Deutsche Boerse AG 02:53:22 2024-05-17 EDT | ||
| 2.04 EUR | -1.92% |
|
| Current month | -11.49% | ||
| 1 month | -2.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 2.04 | -1.92% |
| 24-05-16 | 2.08 | -2.35% |
| 24-05-15 | 2.13 | +1.91% |
| 24-05-14 | 2.09 | -1.42% |
| 24-05-13 | 2.12 | -6.61% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 02:53 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ6LBJ |
| ISIN | DE000SQ6LBJ2 |
| Date issued | 2022-12-20 |
| Strike | 90 $ |
| Maturity | 2024-06-21 (36 Days) |
| Parity | 10 : 1 |
| Emission price | 1.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.39 € |
|---|---|
| Lowest since issue | 0.58 € |
| Spread | 0.06 € |
| Spread % | 2.84% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.86
USD
Average target price
82.93
USD
Spread / Average Target
+22.21%
- Stock Market
- Warrants
- Warrant
